2.10
0.05 (2.44%)
| Previous Close | 2.05 |
| Open | 2.07 |
| Volume | 63,700 |
| Avg. Volume (3M) | 19,261 |
| Market Cap | 297,874,464 |
| Price / Earnings (TTM) | 14.00 |
| Price / Sales | 0.800 |
| Price / Book | 0.710 |
| 52 Weeks Range | |
| TTM Dividend Yield | 5.24% |
| Profit Margin | 6.61% |
| Operating Margin (TTM) | 15.86% |
| Diluted EPS (TTM) | 0.170 |
| Quarterly Revenue Growth (YOY) | -5.40% |
| Quarterly Earnings Growth (YOY) | -19.50% |
| Total Debt/Equity (MRQ) | 12.38% |
| Current Ratio (MRQ) | 5.55 |
| Operating Cash Flow (TTM) | 46.66 M |
| Levered Free Cash Flow (TTM) | 23.58 M |
| Return on Assets (TTM) | 4.11% |
| Return on Equity (TTM) | 5.73% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (MY) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Bullish | |
| Stock | YSPSAH | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Y.S.P. Southeast Asia Holding Bhd is an investment company, that engages in the pharmaceutical business, and provision of management services. It operates through the following segments: Trading, Manufacturing, and Investment Holding. The Trading segment imports, exports, and trades various kinds of pharmaceutical products, and traditional herbal and veterinary products. The Manufacturing segment manufactures pharmaceutical products. The Investment Holding segment focuses on investment holding activity. The firm's majority of revenue comes from the Manufacturing segment. The majority of revenue is concentrated in Malaysia. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 67.81% |
| % Held by Institutions | 0.39% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Aug 2025 | Announcement | Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - DATO' DR LEE FANG HSIN |
| 29 Aug 2025 | Announcement | Changes in Director's Interest (Section 219 of CA 2016) - DATO' DR LEE FANG HSIN |
| 29 Aug 2025 | Announcement | DEALINGS IN LISTED SECURITIES (CHAPTER 14 OF LISTING REQUIREMENTS) : Dealings Outside Closed Period |
| 19 Aug 2025 | Announcement | Quarterly rpt on consolidated results for the financial period ended 30/06/2025 |
| TTM Dividend Yield | 5.24% |
| 5Y Average Dividend Yield | 3.98% |
| Payout Ratio | 47.31% |
| Expected Next Dividend Payment | Jul 2026 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 25 Jun 2025 | 24 Apr 2025 | 25 Jul 2025 | 0.11 Cash |
| 24 Jun 2024 | 22 Apr 2024 | 22 Jul 2024 | 0.11 Cash |
| 26 Jun 2023 | 25 Apr 2023 | 25 Jul 2023 | 0.1 Cash |
| 29 Jun 2022 | 21 Apr 2022 | 25 Jul 2022 | 0.08 Cash |
| 14 Jul 2021 | 26 Apr 2021 | 12 Aug 2021 | 0.08 Cash |
| 27 Jul 2020 | 28 May 2020 | 25 Aug 2020 | 0.08 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2025 | 0.110 | 1 | 5.24 |
| 2024 | 0.110 | 1 | 4.78 |
| 2023 | 0.100 | 1 | 4.35 |
| 2022 | 0.080 | 1 | 3.14 |
| 2021 | 0.080 | 1 | 4.15 |
| 2020 | 0.080 | 1 | 3.51 |
| Show more | |||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |